Read by QxMD icon Read


Xue-Fen Lei, Yang Ke, Tian-Hao Bao, Hao-Ran Tang, Xue-Song Wu, Zhi-Tian Shi, Jie Lin, Zhi-Xian Zhang, Hou Gu, Lin Wang
AIM: To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization (TACE) treatment for intermediate hepatocellular carcinoma (HCC). METHODS: Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B (BCLC-B)] HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. Follow-up was until 2014 or patient death. Two groups were defined in the experiment: The experimental group, treated with sorafenib plus TACE, and the control group, treated with standard TACE alone...
May 16, 2018: World Journal of Clinical Cases
Kentaro Ishikawa, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Sadahisa Ogasawara, Takahiro Maeda, Masayuki Yokoyama, Masanori Inoue, Toru Wakamatsu, Yuko Kusakabe, Tomoko Saito, Akinobu Tawada, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Fumio Imazeki, Naoya Kato
Background and Aim: Transarterial chemoembolization (TACE) is the standard procedure for treating Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC). However, it is often carried out in the treatment of BCLC stage 0/A HCC for various reasons. This study aimed to elucidate the prognosis for BCLC stage 0/A HCC patients treated with TACE or with radiofrequency ablation (RFA). Materials and Methods: The prognosis of 242 BCLC stage 0/A HCC patients within Milan criteria who underwent initially TACE or RFA were retrospectively analyzed using propensity score matching analysis...
April 20, 2018: Oncotarget
Moritz H Albrecht, Thomas J Vogl, Julian L Wichmann, Simon S Martin, Jan-Erik Scholtz, Sebastian Fischer, Renate M Hammerstingl, Marc Harth, Nour-Eldin A Nour-Eldin, Axel Thalhammer, Stephan Zangos, Ralf W Bauer
PURPOSE:  This study was carried out to investigate the impact of abdominal dynamic four-dimensional CT angiography (4D-CTA) for guiding transarterial chemoembolization (TACE) on the amount of contrast material used, operator radiation exposure, catheter consumption, and diagnostic confidence. MATERIALS AND METHODS:  Written consent was waived for this IRB-approved retrospective study. 29 patients (20 men; mean age: 65.7 ± 11.5 years) with malignant liver lesions underwent 4D-CTA, prior to initial TACE...
June 2018: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
Zi-Han Zhang, Wen Zhang, Jun-Ying Gu, Qing-Xin Liu, Jing-Qin Ma, Ling-Xiao Liu, Jian-Hua Wang, Jian-Jun Luo, Zhi-Ping Yan
PURPOSE: To evaluate the safety and efficacy of iodine-125 (125 I) seed strand implantation in combination with transarterial chemoembolization for the treatment of hepatitis B-related unresectable hepatocellular carcinoma (HCC) with portal vein invasion. MATERIALS AND METHODS: From January 2013 to June 2016, 76 HCC patients with type II tumor thrombus were included in this single-center retrospective study. Twenty patients underwent 125 I seed strand implantation combined with transarterial chemoembolization (group A; n = 20), while 56 patients underwent transarterial chemoembolization alone (group B; n = 56)...
May 10, 2018: Journal of Vascular and Interventional Radiology: JVIR
Nevin de Korompay, Mohammed Alshammari, Darren Klass, Frank Y Chou, John Chung, Stephen Ho, David M Liu
PURPOSE: To evaluate cone-beam parenchymal blood volume (PBV) before and after embolization as a predictor of radiographic response to transarterial chemoembolization in unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A phase IIa prospective clinical trial was conducted in patients with HCCs > 1.5 cm undergoing chemoembolization; 52 tumors in 40 patients with Barcelona Clinic Liver Criteria stage B disease met inclusion criteria. Pre- and postembolization PBV analysis was performed with a semiquantitative best-fit methodology for index tumors, with a predefined primary endpoint of radiographic response at 3 months...
May 8, 2018: Journal of Vascular and Interventional Radiology: JVIR
Shalimar, Sushil Jain, Shivanand R Gamanagatti, Saurabh Kedia, Bhaskar Thakur, Baibaswata Nayak, Harpreet Kaur, Deepak Gunjan, Shashi B Paul, Subrat K Acharya
Background/aim: Post-Transarterial Chemoembolization (TACE) Liver Failure (LF) is common in patients with Hepatocellular Carcinoma (HCC). No definitive objective parameters predict its occurrence. We assessed the role of Indocyanine Green (ICG) in prediction of post-TACE LF. Methods: Consecutive HCC patients with Child A/B class, categorized as Barcelona Clinic Liver Cancer (BCLC) staging A/B, were included between August 2012 and July 2014. All underwent ICG dynamics: Plasma Disappearance Rate (PDR) was recorded on the day of TACE...
March 2018: Journal of Clinical and Experimental Hepatology
Dong-Jun Son, Ji-Yun Hong, Ki-Hyun Kim, Young-Hoon Jeong, Dae-Seong Myung, Sung-Bum Cho, Wan-Sik Lee, Yang-Jun Kang, Jin-Woong Kim, Young-Eun Joo
RATIONALE: Liver abscesses caused by Clostridium species infection are extremely rare. PATIENT CONCERNS: The authors report the first case of a liver abscess due to Clostridium haemolyticum, which occurred after transarterial chemoembolization (TACE) for hepatocellular carcinoma, in a 76-year-old woman who presented with right upper quadrant pain and fever. DIAGNOSES: Computed tomography of the abdomen after the second TACE showed an air-filled abscess around a compact, lipiodolized lesion in the right hepatic lobe...
May 2018: Medicine (Baltimore)
Qing Yang, Xiaosheng Jin, Fangpeng Ye, Bingru Zheng, Xiangpang Xie, Ya Luo, Zhenjing Shi, Changsheng Shi
The aim of this study was to explore the difference of liver function change, safety profiles and efficacy of drug-eluting bead transarterial chemoembolization (DEBTACE) therapy between elderly and middle-aged hepatocellular carcinoma (HCC) patients. 91 HCC patients were enrolled in this prospective cohort study. They were treated by DEB-TACE therapy and divided into elderly group (age >= 65 years, n=30) and middle-aged group (age < 65 years, n=61), liver function, safety profiles and treatment response were recorded...
May 8, 2018: Oncology Research
Xia Wu, Ran Chen, Weiliang Zheng, Hongjie Hu
This study aimed to investigate the clinical response and short-term survival and further explore the comprehensive factors for predicting clinical outcomes in patients with liver cancer treated by drug-eluting beads transarterial chemoembolization . Forty-nine patients with liver cancer who received drug-eluting beads transarterial chemoembolization treatment were consecutively enrolled in this cohort study. Demographic features, medical histories, clinicopathological properties, biochemical indexes, previous treatments, and chemoembolization reagents were recorded...
January 1, 2018: Technology in Cancer Research & Treatment
Theodore H Welling, Kevin Eddinger, Kristen Carrier, Danting Zhu, Tyler Kleaveland, Derek E Moore, Douglas E Schaubel, Peter L Abt
Orthotopic liver transplantation (OLT) and resection are effective treatments for hepatocellular carcinoma (HCC). However, optimizing OLT and limiting HCC recurrence remains a vexing problem. New HCC MELD and allocation algorithms provide greater observation of HCC patients, many while receiving local-regional treatments. Potential benefits of local-regional treatment for limiting HCC recurrence post-OLT remain incompletely understood. Therefore we aimed to define HCC specific prognostic factors affecting recurrence in a contemporary, multi-center cohort of HCC patients undergoing OLT and specifically whether local-regional therapies limited recurrence...
May 5, 2018: Liver Transplantation
Shuang Liu, Lei Guo, Hui Li, Bo Zhang, Jialei Sun, Chenghao Zhou, Jian Zhou, Jia Fan, Qinghai Ye
BACKGROUND: It remains uncertain whether patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) benefit from postoperative adjuvant trans-arterial chemoembolization (PA-TACE). METHODS: We retrospectively identified 540 patients to form the crude cohort and adopted propensity score matching analysis to assemble another cohort of 464 patients with similar baseline characteristics. Univariate and multivariate Cox analyses were performed in exploratory subgroups to identify the independent effect of PA-TACE on overall survival (OS)...
May 4, 2018: Annals of Surgical Oncology
Filipe Veloso Gomes, João A Oliveira, Mariana Tomé Correia, Nuno Vasco Costa, João Abrantes, Daniel Torres, Pedro Pereira, Ana Isabel Ferreira, José Hugo Luz, Erik Spaepen, Tiago Bilhim, Élia Coimbra
PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization with polyethylene glycol (PEG) drug-eluting embolic agents in the treatment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A single-center retrospective study of 302 patients (258 men; 85.4%) with HCC treated during a 20-month period was conducted. The mean patient age was 66 years ± 10; 142 (47%) had Barcelona Clinic Liver Cancer stage A disease and 134 had (44.4%) stage B disease; 174 (57...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
Sriharsha Gummadi, Maria Stanczak, Andrej Lyshchik, Flemming Forsberg, Colette M Shaw, John R Eisenbrey
The mainstay of treatment for unresectable hepatocellular carcinoma is locoregional therapy including percutaneous ablation and transarterial chemo- and radioembolization. While monitoring for tumor response after transarterial chemoembolization is crucial, current imaging strategies are suboptimal. The standard of care is contrast-enhanced magnetic resonance imaging or computed tomography imaging performed at least 4 to 6 weeks after therapy. We present a case in which contrast-enhanced ultrasound identified a specific extra-hepatic collateral from the gastroduodenal artery supplying residual viable tumor and assisting with directed transarterial management...
June 2018: Radiology Case Reports
Tanja Zitzelsberger, Roland Syha, Gerd Grözinger, Sasan Partovi, Konstantin Nikolaou, Ulrich Grosse
BACKGROUND: To evaluate the benefits of arterial phase imaging and parenchymal blood volume (PBV) maps acquired by C-arm computed tomography during TACE procedure in comparison to cross-sectional imaging (CSI) using CT or MRI. METHODS: From January 2014 to December 2016, a total of 29 patients with HCC stage A or B (mean age 65 years; range 47 to 81 years, 86% male) were included in this study. These patients were referred to our department for TACE treatment and received peri-interventional C-arm CT...
May 2, 2018: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
Hao Hu, Guo Feng Chen, Wei Yuan, Jian Hua Wang, Bo Zhai
OBJECTIVE: To evaluate the safety and long-term outcomes of microwave ablation (MWA) combined with transarterial chemoembolization (TACE) in a single stage for the treatment of hepatocellular carcinoma (HCC) with a maximum diameter of 5.0-10.0 cm. METHODS: From January 2013 to December 2016, 84 consecutive HCC patients with cirrhosis from two medical centers who underwent MWA-TACE as a first-line treatment for up to three HCCs with maximum diameters of 5.0-10...
May 2, 2018: International Journal of Hyperthermia
Peng Song, Yang Hai, Wantong Ma, Longhe Zhao, Xin Wang, Qinjian Xie, Yang Li, Zhengrong Wu, Yingdong Li, Hongyu Li
BACKGROUND: Primary hepatic carcinoma (PHC) is the third commonest leading to cancer death around the world, and transarterial chemoembolization (TACE) has been proposed as the first-line therapeutic treatment for patients with unresectable PHC. This study aims to determine whether the combination of As2O3 and TACE is superior to alone TACE for achieving more clinical therapeutic efficacy, survival time, life quality and safety in patients with unresectable PHC. METHODS: A comprehensive literature search was conducted on the clinical controlled trials comparing therapeutic effects of As2O3 & TACE versus alone TACE for unresectable PHC through English databases (including PubMed, Embase, and the Cochrane Library) and Chinese databases (including China Knowledge Resource Integrated Database, Wanfang Database, Weipu Database, and Chinese Biomedical Database)...
May 2018: Medicine (Baltimore)
Jodie Chang, Resmi Charalel, Christopher Noda, Raja Ramaswamy, Seung Kwon Kim, Michael Darcy, Gretchen Foltz, Olaguoke Akinwande
AIM: To compare toxicity, response, and survival outcomes of patients with hepatic metastases from breast cancer who underwent transarterial chemoembolization (TACE) or radioembolization (TARE). MATERIALS AND METHODS: A retrospective review was carried out of all patients who underwent TACE or TARE for liver-dominant breast cancer metastases between January 2006 and March 2016 at an academic medical center in the United States. RESULTS: Seventeen patients in the TACE group and 30 patients in the TARE group received 32 TACE and 49 TARE treatments, respectively...
May 2018: Anticancer Research
Krista E Weiss, Daniel Y Sze, Arun A Rangaswami, Carlos O Esquivel, Waldo Concepcion, Edward A Lebowitz, Nishita Kothary, Matthew P Lungren
Children with unresectable HCC have a dismal prognosis and few approved treatment options. TACE is an effective treatment option for adults with HCC, but experience in children is very limited. Retrospective analysis was performed of 8 patients aged 4-17 years (4 male, mean 12.5 years) who underwent TACE for unresectable HCC. Response to TACE was evaluated by change in AFP, RECIST and tumor volume, PRETEXT, and transplantation eligibility by UCSF and Milan criteria. Post-procedure mean follow-up was 8.2 years...
April 29, 2018: Pediatric Transplantation
Jeffrey L Weinstein, Muneeb Ahmed
OBJECTIVE: The purpose of this article is to discuss the use, comparative efficacy, and general technical considerations of percutaneous ablation, alone or in combination with other therapies, for the treatment of hepatocellular carcinoma (HCC). CONCLUSION: Percutaneous ablation is a mainstay treatment for early-stage HCC, offering survival comparable to that of surgical resection for small lesions. It can act as a primary curative therapy or bridge therapy for patients waiting to undergo liver transplant...
April 27, 2018: AJR. American Journal of Roentgenology
Kangshun Zhu, Jingjun Huang, Lisha Lai, Wensou Huang, Mingyue Cai, Jingwen Zhou, Yongjian Guo, Junwei Chen
Purpose To determine the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, S-TACE-RFA) in patients with medium or large (range, 3.1-7.0 cm in diameter) hepatocellular carcinoma (HCC). Materials and Methods This retrospective study evaluated the medical records of consecutive patients with medium or large HCC who underwent S-TACE-RFA or combined TACE and RFA (hereafter, TACE-RFA) from January 2010 to December 2014. Sorafenib was started 3-5 days after TACE, and RFA was performed 1-2 weeks after TACE...
April 24, 2018: Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"